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Purpose: Peritoneal seeding of gastric cancer is known to have a poor prognosis. With the diagnosis of peritoneal seeding, there is no ef-
fective treatment modality. Gastrectomy with chemotherapy or primary chemotherapy is basically one of major options for this condition. 
This study was conducted to compare the clinical outcomes of these treatments and to identify the better way to improve the prognosis 
of patients with peritoneal seeding.
Materials and Methods: Between 2001 and 2007, gastric cancer patients with peritoneal seeding by preoperative or intraoperative 
diagnosis were reviewed retrospectively. The enrolled patients were divided as primary gastrectomy and primary chemotherapy group. 
Clinicopathologic characteristics and clinical outcomes of groups were analyzed and compared.
Results: Fifty-four patients were enrolled. 21 patients belonged to the group of primary gastrectomy and 33 patients were to the primary 
chemotherapy group. Among 33 patients of the primary chemotherapy group, 17 patients were received only chemotherapy and 16 pa-
tients were received gastrectomy due to the good responses of primary chemotherapy. The 3 years survival rates were 14% in primary 
gastrectomy group, 55% in patients who received gastrectomy after primary chemotherapy, and 0% in patients with primary chemo-
therapy only. 
Conclusions: Although this study had many limitations, some valuable information was produced. In terms of survival benefits for the 
gastric cancer patients with peritoneal seeding, primary gastrectomy and additional gastrectomy after primary chemotherapy revealed 
the better clinical outcomes. But, prospective randomized clinical study and multi-center study are should be performed to decide proper 
treatment for gastric cancer patients with peritoneal seeding.
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Introduction
The prevalence of early stage of gastric cancer patients is in-
creasing annually due to popularization of gastroscopy and these 
are treated with various methods at early stage of the disease de-
pending on how progressive the disease is. However, when the 
disease progresses continuously or recurrence, peritoneal seeding is 
commonly observed during the pathological course and this causes 
a major concern during the treatment and poor prognosis. 
The survival time of gastric cancer patients with peritoneal 
seeding is reported to be 3~9 months.(1-3) Although managements 
such as systematic chemotherapy, peritonectomy, intra-peritoneal 
chemotherapy and heat therapy are applied to improve the progno-
sis of advanced gastric cancer with peritoneal seeding, satisfactory 
methods has not yet found.(4,5) Recently, neo-adjuvant chemo-
therapy has been applied in various cancers and the results of neo-
adjuvant chemotherapy have been satisfactory. Therefore, primary 
chemotherapy is applicable for gastric cancer patients.(6,7) In 
gastric cancer, the concept of primary chemotherapy is recognized 
as a contemporary form of treatment for advanced gastric cancer 
patients who are too difficult to undergo radical gastrectomy and Bae JM, et al.
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it has been reported in numerous research that a better prognosis 
is expected if gastrectomy is done to the patients who had a good 
response to primary chemotherapy.(8,9) The research findings are 
continuously shown that when primary gastrectomy was performed 
actively prior to chemotherapy, the response to the chemotherapy 
increased and resulted in the improved prognosis.(10-12) There-
fore, the careful consideration is required to choose a treatment 
option between primary chemotherapy and primary gastrectomy. 
Although the status of the disease at the time of diagnosis is an im-
portant variable to make a decision, the clinical outcomes of each 
treatment can be also considered when the decision is made. The 
researchers in this study intend to provide the clinical outcomes 
that need to be aware of to choose treatment plans for the gastric 
cancer patients with peritoneal seeding after comparing the clinical 
condition and the prognosis of the patients who had primary che-
motherapy to those of the patients who had primary gastrectomy 
among the gastric cancer patients with peritoneal seeding. 
Materials and Methods
The subjects were the patients in this hospital who diagnosed 
metastatic gastric cancer with P1 or P2, but no further metastasis, 
between January 2001 and December 2007. The patients who had 
further metastasis to other organs or the patients who were in P3 
stage of peritoneal seeding were excluded from this study. 
Peritoneal seeding was diagnosed by laparoscopic exploration 
and it was performed when peritoneal seeding was suspected pre-
operatively by serosal invasion, thick peritoneum or ascites which 
can be found on abdominal computerized tomography. The cases 
which the diagnosis was made after incision of upper abdominal 
median line but yet peritoneal seeding was not suspected preopera-
tively were all also included. 
In terms of treatment choice, gastrectomy was performed as far 
as possible, except that it was not impossible to do surgical dissec-
tion and excision due to conglomeration caused by infiltration to 
other organs (T4). Also, gastrectomy was performed for chronic 
bleeding or obstruction from primary tumor site. All the patients 
who had gastrectomy also underwent chemotherapy afterwards. 
The patients who did not have gastrectomy had chemotherapy 
first; this group of patients was classified as a primary chemo-
therapy group. The combination chemotherapy method was used 
with Cisplatin and 5-FU in both the primary chemotherapy group 
and the gastrectomy group. In cases of deterioration, continued 
chemotherapy by changing the formula to the ones with Docetaxel, 
Paclitaxel, and Irinotecan.
The evaluation of chemotherapy response in the primary 
chemotherapy group was done by performing gastroscopy and 
abdominal computed tomography (CT) or positron emission to-
mography (PET)-CT within 3 months after the first dose of che-
motherapy. Whether gastric cancer is getting worse or responding 
to chemotherapy was judged by comparing the improvement of 
primary tumor range and ulcer with gastroscopy and the changes 
of existing lymphadenopathy and the onset of new lesions with ab-
dominal CT or PET-CT.
If there is evidence that the primary tumor and the condi-
tion of inside peritoneum is improving on the above examination, 
laparoscopic exploration was performed once again to confirm the 
status of peritoneal seeding. Providing it is judged to be improved, 
gastrectomy was performed additionally but, supposing the patients 
didn’t respond to the chemotherapy or it showed the evidence 
of deterioration, continued with chemotherapy after changing its 
formula instead of doing gastrectomy (Fig. 1). At least D2 level of 
lymph node dissection was performed with all the gastrectomy. 
Retrospective analysis was carried out based on the records 
made after surgery regarding clinicopathologic characteristics such 
as operation methods, tumor size, Borrmann’s type, degree of cell 
differentiation, Lauren’s type, invasion depth, and lymph node 
stage.
SPSS 12.0 (SPSS Inc., Chicago, IL, USA) used for statistical 
Fig. 1. Patients selection algorithm for the treatment of gastric cancer 
patients with peritoneal seeding.Clinical Result in Gastric Cancer with Seeding
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analysis, Chi-square test for Cross tabulation Analysis, Kaplan-
Meier method for survival analysis and the significance was proved 
wit log-rank test and it is regarded as statistically significant if P- 
value is less than 0.05 (P＜0.05 ).
Results
The total number of patients was 54 people. 21 patients were in 
the primary gastrectomy group and 33 patients were in the primary 
chemotherapy group and the male versus female ratio was 2 : 1 and 
1.8 : 1 respectively. The age ranged between 32 years old and 75 
years old and the average age was 53 years old. The average age of 
the primary gastrectomy group was 54.9 years old and that of the 
primary chemotherapy was 56.2 years old showing no significant 
difference (Table 1). 
The stage of peritoneal seeding (P) was evaluated referencing 
Japanese Classification of Gastric Carcinoma.(13) Table 1 shows the 
range. There was no significant difference in the proportion of P 
between two groups. 
17 patients from the primary chemotherapy group did not show 
any signs of improvement and subsequently, they were not received 
to have gastrectomy and continued with only chemotherapy. The 
other 16 patients from the same group showed the improvement on 
the examinations and they had gastrectomy after 2~12 months (5.6 
months in average) since the treatment started. Splenectomy was 
performed with gastrectomy to 3 cases from the primary gastrec-
tomy group and 4 cases from the primary chemotherapy group. 
Table 1. Characteristics of preoperative chemotherapy group 
and primary gastrectomy group in gastric cancer patients with 
peritoneal seeding
Preoperative 
chemotherapy 
group* (n=33)
%
Primary
gastrectomy 
group* (n=21)
%
Sex
   Male
   Female
Mean age
P stage
   P1
   P2
21
12
56.2
21
12
63.6
36.3
63.6
36.3
14
7
54.9
9
12
66.6
33.3
42.8
57.1
*No statistical diff  erence between groups.
Table 2. Clinicopathologic characteristics of gastric cancer patients with peritoneal seeding who received gastrectomy
Gastrectomy aft  er
preoperative
chemotherapy
group (n=16)
%
Primary
gastrectomy
group (n=21)
%
Gastrectomy type Subtotal
Total
  5
11
31.2
68.7
12
  9
57.1
42.8
Combined resection Splenectomy   4 25.0   3 14.3
Mean tumor size 7.12 cm 6.99 cm
Borrmann type I   0   0.0   5 23.8
II   0   0.0   5 23.8
III 13 81.2 10 47.6
IV   3 18.7   4 19.0
Cell type Diff  erentiated   6 37.5 14 61.8
Undiff  erentiated 10 62.4 13 47.6
Lauren type Intestinal   4 25.0   3 14.2
Diff  use   8 50.0 12 61.9
Mixed   4 25.0   5 23.8
Depth of invasion pT3   7 43.7   1   4.7
pT4a   7 43.7 16 76.1
pT4b   2 12.4   4 19.0
N stage N1   3 18.7   7 33.3
N2   7 43.7   5 23.8
N3   6 37.5   9 42.8Bae JM, et al.
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Comparing clinicopathologic characteristics of each group after 
performing gastrectomy, the average tumor size, Borrmann’s type, 
invasion depth and the stage of lymph node showed no significant 
difference. The degree of histodifferentiation showed both undif-
ferentiated forms in both groups (Table 2). 
The tracing period was 36±12 months and the total 3 year sur-
vival rate was 21.3%. The 3 year survival rate of the patients who 
had additional gastrectomy from the primary chemotherapy group 
was 55.3% and the average survival time was 36 months and the 3 
year survival rate of the primary gastrectomy group was 14.2% and 
the survival time was 20 months. The survival rate of the patients 
who continued chemotherapy from the primary chemotherapy 
group was 0% and the average survival time was 10 months; statis-
tically significant differences were evident between the groups (Fig. 
2).
No operation or chemotherapy related mortality or morbidity 
were found among the patients. 
Discussion
In recent years, although the number of early stage of gastric 
patients is increasing, advanced cases are still found and if there is 
peritoneal seeding, the prognosis can be poor. 
Because of the poor prognosis, standard conventional chemo-
therapy would be preferably considered, however, intra-peritoneal 
and systemic combined chemotherapy, intra-peritoneal heat 
therapy with cytoreductive surgery, active peritonectomy, induction 
chemotherapy and post-operation chemotherapy. are recently try-
ing to improve the prognosis.(10,14-16) Furthermore, gastrectomy 
in the gastric cancer with peritoneal seeding is known to increase 
the response of chemotherapy, subsequently, improved prognosis.
(10-12) Therefore, the authors compared the clinical characteris-
tics and the prognosis according to primary treatments of gastric 
cancer with peritoneal seeding. Laparoscopy made easy for us to 
decide the treatment method because it made possible to find out 
about the level of peritoneal seeding precisely without unnecessary 
laparotomy when peritoneal seeding is suspected. It is reported that 
the accuracy of non-invasive diagnosis prior to surgery is about 
58~63% and the sensitivity is lower in the case of peritoneal micro 
metastasis.(17) Comparing to this, the sensitivity of laparoscopic 
exploration is reported to be above 90%.(18) The diagnosis with 
peritoneal cytology is different from the one with laparoscopy in 
many ways, there was no significant difference in actual diagnosis 
between two.(19)
The total 3 year survival rate was 21.3% in this study but, com-
paring to this, the total 3 year survival rate was reported to be 
about 15% in the study of Yonemura et al.(20) and was reported to 
be about 18% in the study of Glehen et al.(21). In detail, the 3 year 
survival rate of the patients who had gastrectomy after primary 
chemotherapy was 55.3% in this study and Yonemura et al.(20) 
also reported more than 50% but Badgwell et al.(22) reported only 
12% in their study. The 3 year survival rate in the primary gastrec-
tomy group was 14.2% in this study and it was 12.9% in the study 
of Hioki et al.(23). It was 0% in the patients who continued with 
alternative chemotherapy according to the result of response test 
and Badgwell et al.(22) also reported the same figure. Although 
research methods, difference between the group of patients and 
treatment methods were rather different in all those studies, the 
survival rate in this study was similar to the other studies overall. 
When gastric cancer patients had unexpected peritoneal seeding 
after exploration, it was inevitable to close without any procedure. 
However, the researchers in this study tried to do gastrectomy and 
gastrectomy with other excision, peritonectomy and D2 above 
lymph node dissection as long as possible. Kwon(24) and Seo et 
al.(25) claimed that radical curability could be achieved by gastrec-
tomy and removal of metastasis when the stage of peritoneal seed-
ing was in P1 and Hioki et al.(23) claimed the improvement of the 
prognosis can be also expected by gastrectomy when the peritoneal 
seeding was not progressed any further P2. Even the stage of P3, 
Yonemura et al.(20) did induction chemotherapy to 61 patients with 
P3 and they claimed that 50% of those patients, that is 30 patients 
in number, were operated gastrectomy additionally. Like this, Pol-
Fig. 2. Survival curves for gastric cancer patients with peritoneal seed-
ing according to primary treatment.Clinical Result in Gastric Cancer with Seeding
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lock and Roth(26) pointed out that removal of primary tumor 
reduced the obstruction, bleeding, perforation and ascites caused by 
the primary tumor and made patients more comfortable. It also in-
creases the efficacy of chemotherapy by reducing the size of tumor 
and there is immunological benefits by reducing the level of body 
metabolism and cytokine, the immunosuppressant that produced 
by tumors.
It is necessary to have clear plans for the methods and the time 
of response tests and the period of chemotherapy because the re-
sponse to chemotherapy is an important variable even though che-
motherapy is performed primarily and it is important to judge the 
possible time of radical gastrectomy. The period of chemotherapy 
in primary chemotherapy of gastric patients with peritoneal seed-
ing is thought to be varied depending on the response to the che-
motherapy. Considering the experience of the researchers in this 
study, some patient were qualified to have gastrectomy just after 
twice of chemotherapy with quick response and some of the others 
showed more gradual improvement over the 12 month period and 
finally were able to have the operation. Yonemura et al.(20) also 
said between 2 times and 6 times of chemotherapy were carried out 
depending on the patients and Yoon et al.(27) said between 3 times 
and 7 times of chemotherapy were carried out prior to gastrectomy 
which showed that the period of chemotherapy can be varied. 
Because the prognosis of the primary chemotherapy group was 
better than that of the primary gastrectomy group, if the reduction 
of tumor is achieved by chemotherapy as happened in 16 out of 
33 patients in the primary chemotherapy group, it is expected to 
increase the possibility of radical gastrectomy and the subsequent 
survival rate by lowering the disease stage. 
Generally, gastric cancer patients with peritoneal seeding receive 
primary chemotherapy without consideration of primary gastrecto-
my. But, someone who does not respond to primary chemotherapy 
should receive primary gastrectomy to improve prognosis.
More researches regarding appropriate primary treatments for 
the patient with peritoneal seeding are thought to be required be-
cause it is possible that primary gastrectomy might be more ben-
eficial for them in terms of the prognosis. Therefore, it is necessary 
to compare between the efficacy of primary chemotherapy and 
primary gastrectomy with well-designed prospective randomized 
clinical study. 
There are some limitations in this study. First of all, because 
the size and the depth of primary lesion, Borrmann’s type and the 
level of affected lymph node were largely different, there can be a 
lack of consideration on these factors. Additionally, it can be less 
objective to judge the conglomeration status that makes impossible 
to operate gastrectomy when the decision is made to do primary 
gastrectomy. Finally, there is a possibility for subjective interfer-
ence when the response to chemotherapy was evaluated with the 
results of gastroscopy, abdominal CT and PET because the unique 
Korean standard and the international standard to judge the re-
sponse of chemotherapy are ambiguous. Hence, the objective and 
detailed standard to judge the response of chemotherapy in gastric 
cancer is necessary. Currently, the combination chemotherapy is 
the most commonly used in chemotherapy for gastric cancer and 
the formula of this vary depending on clinician. As a result, it is not 
feasible to decide a treatment depending on the response after hav-
ing chemotherapy under circumstances where there is no objectifi-
cation for the formula.
Although it is difficult to generalize the results of this study, it 
is thought to be beneficial to perform gastrectomy actively when 
feasible. 
To improve prognosis of gastric cancer patients with peritoneal 
seeding, when these patients receive primary chemotherapy, it is 
important to actively consider gastrectomy, depending on the re-
sponse to chemotherapy.
It is also necessary to make comparison between the efficacy of 
primary chemotherapy and that of primary gastrectomy through 
well-designed prospective randomized clinical study in order to 
establish the treatment guidance for the gastric cancer with perito-
neal seeding. 
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